Sattva S. Neelapu, M.D.

Peer-Reviewed Articles

1. Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol:JCO2302786. e-Pub 2024. PMID: 39094076.
2. Szymura SJ, Wang L, Zhang T, Cha SC, Song J, Dong Z, Anderson A, Oh E, Lee V, Wang Z, Parshottam S, Rao S, Olsem JB, Crumpton BN, Lee HC, Manasanch EE, Neelapu S, Kwak LW, Thomas SK. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. Nat Commun 15(1):6874, 2024. e-Pub 2024. PMID: 39128904.
3. Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua M, An X, Bandey IN, Montalvo MJ, Adolacion JRT, Saeedi A, Sadeghi F, Fousek K, Puebla-Osorio N, Cooper LJN, Bernatchez C, Singh H, Ahmed N, Mattie M, Bot A, Neelapu S, Varadarajan N. Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat Cancer 5(7):1010-1023, 2024. e-Pub 2024. PMID: 38750245.
4. Oluwole OO, Neelapu SS, Ray MD, Limbrick-Oldfield EH, Wade SW, Kanters S, Patel AR, Locke FL. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert Rev Anticancer Ther 24(6):457-465, 2024. e-Pub 2024. PMID: 38646700.
5. Jallouk AP, Kui N, Sun R, Westin JR, Steiner RE, Nair R, Nastoupil LJ, Fayad LE, Zaki AA, Hawkins M, Adkins S, Noorani M, Das K, Henderson J, Shpall EJ, Kebriaei P, Ramdial J, Flowers CR, Neelapu SS, Ahmed S, Strati P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2024. PMID: 38031807.
6. Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Owen J, Kanters S, Bobillo S, Ribiero MT, Jacobson CA, Neelapu SS, Ghesquieres H, Nahas M, Beygi S, Patel AR, Gribben JG. A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 24(5):e191-e195.e6, 2024. e-Pub 2024. PMID: 38365528.
7. Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol 99(5):880-889, 2024. e-Pub 2024. PMID: 38504387.
8. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5). Blood 143(6):496-506, 2024. e-Pub 2023. PMID: 37879047.
9. Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos D, Neelapu SS, Locke FL, Ghobadi A. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium. Blood Adv 8(4):1042-1050, 2024. e-Pub 2023. PMID: 38051550.
10. Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. e-Pub 2023. PMID: 37822075.
11. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
12. Li X, Henderson J, Gordon MJ, Sheikh I, Nastoupil LJ, Westin J, Flowers C, Ahmed S, Wang L, Neelapu SS, Strati P, Deng Q, Green MR. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell 41(11):1835-1837, 2023. e-Pub 2023. PMID: 37738975.
13. Chu F, Cao J, Liu J, Yang H, Davis TJ, Kuang SQ, Cheng X, Zhang Z, Karri S, Vien LT, Bover L, Sun R, Vega F, Green M, Davis RE, Neelapu SS. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. J Immunother Cancer 11(11), 2023. e-Pub 2023. PMID: 38007239.
14. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. PMID: 37586321.
15. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Transplant Cell Ther 29(7):438.e1-438.e16, 2023. e-Pub 2023. PMID: 36906275.
16. Strati P, Pasvolsky O, Feng L, Xu G, Tewari SO, Varghese J, Ow K, Santiago M, Al Zaki A, Jallouk A, Neelapu SS, Kebriaei P, Shpall EJ, Ahmed S. ASCT vs CART for Patients with Relapsed LBCL in PR: Role of TMTV. Blood Adv 7(11):2586-2589, 2023. e-Pub 2023. PMID: 36745104.
17. Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Singareeka Raghavendra A, Yang-Kolodji G, Chu F, Neelapu SS, Marchese A, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res 25(1):62, 2023. e-Pub 2023. PMID: 37280713.
18. Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41(6):1032-1047.e4, 2023. PMID: 37311413.
19. Wang XS, Srour SA, Mendoza T, Whisenant M, Subbiah I, Gonzalez E, Kamal M, Shen SE, Cleeland C, Kebriaei P, Rezvani K, Neelapu S, Ahmed S, Shpall E. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. Br J Haematol 201(4):738-746, 2023. e-Pub 2023. PMID: 36733986.
20. Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 41(14):JCO2201797, 2023. e-Pub 2023. PMID: 36753699.
21. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood 141(19):2307-2315, 2023. e-Pub 2023. PMID: 36821768.
22. Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv 7(7):1137-1145, 2023. e-Pub 2022. PMID: 36375046.
23. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108(4):1163-1167, 2023. e-Pub 2023. PMID: 36384251.
24. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
25. Wang Z, Zhang T, Anderson A, Lee V, Szymura S, Dong Z, Kuang B, Oh E, Liu J, Neelapu SS, Kwak L, Cha SC. Immortalized B Cells Transfected with mRNA of Antigen Fused to MITD (IBMAM): An Effective Tool for Antigen-Specific T-Cell Expansion and TCR Validation. Biomedicines 11(3), 2023. e-Pub 2023. PMID: 36979775.
26. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
27. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2022. PMID: 35952327.
28. Palomba ML, Ghione P, Patel AR, Nahas M, Beygi S, Hatswell AJ, Kanters S, Limbrick-Oldfield EH, Wade SW, Ray MD, Owen J, Neelapu SS, Gribben J, Radford J, Bobillo S. A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Expert Rev Anticancer Ther 23(2):199-206, 2023. e-Pub 2023. PMID: 36723678.
29. Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Raghavendra AS, Yang-Kolodji G, Chu F, Neelapu SS, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Res Sq, 2023. e-Pub 2023. PMID: 36824840.
30. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2022. PMID: 36068929.
31. Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
32. Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. PMID: 36384092.
33. Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk 22(10):753-759, 2022. e-Pub 2022. PMID: 35780055.
34. Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res 121:106928, 2022. e-Pub 2022. PMID: 35963025.
35. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
36. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov 3(5):428-443, 2022. e-Pub 2022. PMID: 35687817.
37. Romain G, Strati P, Rezvan A, Fathi M, Bandey IN, Adolacion JRT, Heeke D, Liadi I, Marques-Piubelli ML, Solis LM, Mahendra A, Vega F, Cooper LJ, Singh H, Mattie M, Bot A, Neelapu SS, Varadarajan N. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. J Clin Invest 132(17), 2022. e-Pub 2022. PMID: 35881486.
38. Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Chou J, Plaks V, Wang Z, Xue A, Mattie M, Rossi JM, Bot A, Galon J. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med 28(9):1872-1882, 2022. e-Pub 2022. PMID: 36038629.
39. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
40. Ghione P, Palomba ML, Patel AR, Bobillo S, Deighton K, Jacobson CA, Nahas M, Hatswell AJ, Jung AS, Kanters S, Snider JT, Neelapu SS, Ribeiro MT, Brookhart MA, Ghesquieres H, Radford J, Gribben JG. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood 140(8):851-860, 2022. e-Pub 2022. PMID: 35679476.
41. Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma. Haematologica 107(7):1555-1566, 2022. e-Pub 2022. PMID: 34758610.
42. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. e-Pub 2022. PMID: 35359004.
43. Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy. Blood Adv 6(9):2867-2871, 2022. e-Pub 2022. PMID: 35015825.
44. Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, Feng L, Watson G, Ayers A, Neelapu SS, Khurana A, Lin Y, Iqbal M, Merryman RW, Strati P. A Multicenter Retrospective Study of Polatuzumab Vedotin in Patients with Large B-cell Lymphoma After CAR T-cell Therapy. Blood Adv 6(9):2757-2762, 2022. e-Pub 2022. PMID: 35240681.
45. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med 28(4):735-742, 2022. e-Pub 2022. PMID: 35314842.
46. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
47. Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun 13(1):2228, 2022. e-Pub 2022. PMID: 35484100.
48. Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica 107(3):690-701, 2022. e-Pub 2022. PMID: 33792219.
49. Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv 6(4):1143-1151, 2022. e-Pub 2022. PMID: 35015819.
50. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85-96, 2022. e-Pub 2021. PMID: 34601571.
51. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23(1):91-103, 2022. e-Pub 2021. PMID: 34895487.
52. Singh S, Roszik J, Saini N, Singh VK, Bavisi K, Wang Z, Vien LT, Yang Z, Kundu S, Davis RE, Bover L, Diab A, Neelapu SS, Overwijk WW, Rai K, Singh M. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Front Immunol 13:794684, 2022. e-Pub 2022. PMID: 35720386.
53. Ragoonanan D, Bhar S, Mohan G, Beltramo F, Khazal SJ, Hurley C, Andersen C, Margossian S, Neelapu SS, Shpall E, Gutierrez C, Tewari P, Shoberu B, Talleur A, McCall D, Nunez C, Cuglievan B, Tambaro FP, Petropoulos D, Abdel-Azim H, Mahadeo KM. A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. Front Oncol 12:1022901, 2022. e-Pub 2022. PMID: 36353531.
54. Wang XS, Srour SA, Whisenant M, Subbiah IM, Chen TH, Ponce D, Gonzalez AG, Kamal M, Mendoza T, Cleland CS, Kebriaei P, Neelapu SS, Rezvani K, Ahmed S, Shpall E. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplant Cell Ther 27(11):930.e1-930.e10, 2021. e-Pub 2021. PMID: 34265479.
55. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
56. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) versus salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv 5(20):4149-4155, 2021. e-Pub 2021. PMID: 34478487.
57. Whisenant MS, Srour SA, Williams LA, Subbiah I, Griffin D, Ponce D, Kebriaei P, Neelapu SS, Shpall E, Ahmed S, Wang XS. The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Semin Oncol Nurs:151216. e-Pub 2021. PMID: 34629213.
58. Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan PM, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138(12):1081-1085, 2021. e-Pub 2021. PMID: 34041526.
59. Handley G, Khawaja F, Kondapi DS, Lee HJ, Kaufman GP, Neelapu SS, Fayad LE, Tummala S, Chi L, Strati P, Mulanovich VE. Human Herpesvirus-6 Myelitis after Chimeric Antigen Receptor T-cell Therapy. Int J Infect Dis. e-Pub 2021. PMID: 34600133.
60. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):435-453, 2021. e-Pub 2021. PMID: 33608690.
61. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. PMID: 34264268.
62. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
63. Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen B, Neelapu SS, Yee C, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34205020.
64. Nair R, Drillet G, Lhomme F, Le Bras A, Michel L, Rossi J, Sherman M, Xue A, Kerber A, Jittapiromsak N, Chi L, Tummala S, Neelapu SS, Houot R. Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica 106(5):1504-1506, 2021. e-Pub 2021. PMID: 32732365.
65. Mamlouk O, Nair R, Iyer SP, Edwards A, Neelapu SS, Steiner RE, Adkins SA, Hawkins M, Saini N, Devashish K, Strati P, Mandayam S, Ahmed S. Safety and Efficacy of CAR T-Cell Therapy in Kidney Transplant Recipients. Blood 137(18):2558-2562, 2021. e-Pub 2020. PMID: 33512386.
66. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. Blood 137(8):1124-1129, 2021. e-Pub 2020. PMID: 32932518.
67. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
68. Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 8(2), 2020. PMID: 33335028.
69. Neelapu SS, Adkins S, Ansell SM, Brody J, Cairo MS, Friedberg JW, Kline JP, Levy R, Porter DL, van Besien K, Werner M, Bishop MR. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer 8(2), 2020. PMID: 33361336.
70. Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(19):4898-4911, 2020. PMID: 33035333.
71. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 38(27):JCO1902104, 2020. e-Pub 2020. PMID: 32401634.
72. Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, Lin Y, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, Athale J, Shah NN, Kochenderfer JN, Dharshan A, Beitinjaneh A, Arias AS, McEvoy C, Mead E, Stephens RS, Nates JL, Neelapu SS, Pastores SM. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care 58:58-64, 2020. e-Pub 2020. PMID: 32361219.
73. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. PMID: 32822484.
74. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(7):1907-1913, 2020. e-Pub 2019. PMID: 31601688.
75. Kohorst MA, Nunez CA, Tewari P, Petropoulos D, Mahadeo KM, Neelapu SS, Shpall EJ, Khazal S. Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. Br J Haematol 190(2):e114-e117, 2020. e-Pub 2020. PMID: 32469086.
76. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 4(13):2871-2883, 2020. PMID: 32589728.
77. Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 4(13):3123-3127, 2020. PMID: 32645136.
78. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
79. Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 135(23):2106-2109, 2020. PMID: 32181801.
80. Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol 95(5):510-520, 2020. e-Pub 2020. PMID: 32052473.
81. Locke FL, Go WY, Neelapu SS. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. JAMA Oncol 6(2):1-10, 2020. e-Pub 2019. PMID: 31697310.
82. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. PMID: 32023374.
83. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(12):2305-2321, 2019. e-Pub 2019. PMID: 31446199.
84. Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z, Liu J, Jiang ZY, Luong AU, Peng W, Wang J, Balakrishnan K, Yee C, Dong C, Davis RE, Watowich SS, Neelapu SS. CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia 33(11):2640-2653, 2019. e-Pub 2019. PMID: 31028278.
85. Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv 3(15):2400-2408, 2019. PMID: 31405950.
86. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94(6):E150-E153, 2019. e-Pub 2019. PMID: 30785215.
87. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection. Blood 133(26):2800-2802, 2019. e-Pub 2019. PMID: 31101626.
88. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25(4):625-638, 2019. e-Pub 2018. PMID: 30592986.
89. Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 16(1):45-63, 2019. PMID: 30082906.
90. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20(1):31-42, 2019. e-Pub 2018. PMID: 30518502.
91. Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer 6(1):137, 2018. e-Pub 2018. PMID: 30514386.
92. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47-62, 2018. e-Pub 2017. PMID: 28925994.
93. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(26):2531-2544, 2017. e-Pub 2017. PMID: 29226797.
94. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800-1808, 2017. e-Pub 2017. PMID: 28774879.
95. Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, Bernatchez C, Kwak LW, Neelapu SS, Nurieva R. Absence of Grail promotes CD8(+) T cell anti-tumour activity. Nat Commun 8(1):239, 2017. e-Pub 2017. PMID: 28798332.
96. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther 25(1):285-295, 2017. e-Pub 2017. PMID: 28129122.
97. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS,* Fowler NH* (*equal contribution). Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 2016. e-Pub 2016. PMID: 26802151.
98. Weng J, Baio FE, Moriarty KE, Torikai H, Wang H, Liu Z, Maiti SN, Gwak D, Popescu MS, Cha SC, Cooper LJ, Neelapu SS, Kwak LW. Targeting B-cell malignancies through human B-cell receptor specific CD4 T cells. Oncoimmunology 5(11):e1232220, 2016. e-Pub 2016. PMID: 27999743.
99. Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 135(12):2834-46, 2014. e-Pub 2014. PMID: 24771328.
100. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
101. Liu X, Chen X, Zhong B, Wang A, Wang X, Chu F, Nurieva RI, Yan X, Chen P, van der Flier LG, Nakatsukasa H, Neelapu SS, Chen W, Clevers H, Tian Q, Qi H, Wei L, Dong C. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature 507(7493):513-8, 2014. e-Pub 2014. PMID: 24463518.
102. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. e-Pub 2013. PMID: 24332512.
103. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 190(12):6681-93, 2013. e-Pub 2013. PMID: 23686488.
104. Cha SC, Qin H, Kannan S, Rawal S, Watkins LS, Baio FE, Wu W, Ong J, Wei J, Kwak B, Kim S, Popescu MS, Paick DS, Kim K, Luong A, Davis RE, Schroeder HW, Kwak LW, Neelapu SS. Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol 190(9):4887-98, 2013. e-Pub 2013. PMID: 23536634.
105. Foglietta M,* Neelapu SS,* (*equal contribution), Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant 48(2):269-77, 2013. e-Pub 2012. PMID: 22773122.
106. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 120(8):1613-23, 2012. e-Pub 2012. PMID: 22645177.
107. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
108. Westin JR, Gibbs A, Mills KR, Neelapu SS. Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula. Case Report Med 2012:457908, 2012. e-Pub 2012. PMID: 22811723.
109. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain specific cytotoxic T lymphocytes. Clin Cancer Res 17(18):5945-52, 2011. e-Pub 2011. PMID: 21813633.
110. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, Wang YH, Lim H, Reynolds JM, Zhou XH, Fan HM, Liu ZM, Neelapu SS, Dong C. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 17(8):983-8, 2011. e-Pub 2011. PMID: 21785430.
111. Schuster SJ,* Neelapu SS,* (*equal contribution) Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29(20):2787-94, 2011. e-Pub 2011. PMID: 21632504.
112. Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 27(18):3036-43, 2009. e-Pub 2009. PMID: 19414675.
113. Lee ST, Liu S, Radvanyi L, Sukhumalchandra P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizée G, Neelapu SS. A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods 331(1-2):13-26, 2008. e-Pub 2007. PMID: 17959194.
114. Neelapu SS, Gause BL, Harvey L, Lee ST, Frye AR, Horton J, Robb RJ, Popescu MC, Kwak LW. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 109(12):5160-3, 2007. e-Pub 2007. PMID: 17339422.
115. Popescu MC, Robb RJ, Batenjany MM, Boni LT, Neville ME, Pennington RW, Neelapu SS, Kwak LW. A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood 109(12):5407-10, 2007. e-Pub 2007. PMID: 17351111.
116. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13(3):958-64, 2007. PMID: 17289891.
117. Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11(9):986-91, 2005. e-Pub 2005. PMID: 16116429.
118. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C, Barlogie B, Kwak LW. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 36(4):315-23, 2005. PMID: 15968284.
119. Neelapu SS, Baskar S, Gause BL, Kobrin CB, Watson TM, Frye AR, Pennington R, Harvey L, Jaffe ES, Robb RJ, Popescu MC, Kwak LW. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res 10(24):8309-17, 2004. PMID: 15623607.

Invited Articles

1. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85-96, 2022. e-Pub 2021. PMID: 34002066.
2. Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ. Chimeric Antigen Receptor T-cell Therapy Toxicities. Br J Clin Pharmacol 87(6):2414-2424, 2021. e-Pub 2020. PMID: 32463929.
3. Reagan PM, Neelapu SS. How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. J Clin Oncol 39(5):456-466, 2021. e-Pub 2021. PMID: 33434058.
4. Fang PQ, Gunther JR, Wu SY, Dabaja BS, Nastoupil LJ, Ahmed S, Neelapu SS, Pinnix CC. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Front Oncol 11:648655, 2021. e-Pub 2021. PMID: 33842363.
5. Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol 37 Suppl 1:48-52, 2019. PMID: 31187535.
6. Strati P, Neelapu SS. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Curr Oncol Rep 21(5):38, 2019. e-Pub 2019. PMID: 30919158.
7. Nair R, Neelapu SS. The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol 31(3):293-298, 2018. e-Pub 2018. PMID: 30213399.
8. Sathyanarayanan V, Neelapu SS. Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Mol Oncol 9(10):2043-53, 2015. e-Pub 2015. PMID: 26548534.
9. Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol 27(5):384-91, 2015. PMID: 26248256.
10. Nastoupil LJ, Neelapu SS. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. Curr Oncol Rep 17(7):30, 2015. PMID: 25986722.
11. Chu F, Neelapu SS. Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets. Oncoimmunology 3(1):e28101, 2014. e-Pub 2014. PMID: 24808975.
12. Westin JR, Neelapu SS. Therapy of newly diagnosed follicular lymphoma. Front Oncol 2:188, 2012. e-Pub 2012. PMID: 23248775.
13. Kannan S, Neelapu SS. Vaccination strategies in follicular lymphoma. Curr Hematol Malig Rep 4(4):189-95, 2009. PMID: 20425407.
14. Park HJ, Neelapu SS. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol 142(2):179-91, 2008. e-Pub 2008. PMID: 18422783.
15. Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Expert Opin Biol Ther 7(1):113-22, 2007. PMID: 17150023.
16. Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW. Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines 5(3):381-94, 2006. PMID: 16827622.

Editorials

1. Saini N, Neelapu SS. CAR Treg cells: prime suspects in therapeutic resistance. Nat Med 28(9):1755-1756, 2022. PMID: 36109644.
2. Strati P, Neelapu SS. CAR-T failure: beyond antigen loss and T cells. Blood 137(19):2567-2568, 2021. PMID: 33983421.
3. Green MR, Neelapu SS. Not so FASt: Tumor cells resisting death drive CAR T-cell dysfunction. Cancer Discov 10(4):492-494, 2020. PMID: 32238396.
4. Neelapu SS. A CAR against CAR for unintended consequences. Blood 135(7):460-462, 2020. PMID: 32197269.
5. Coscia M, Bruno B, Neelapu S. Editorial: CAR T-Cell Therapies in Hematologic Tumors. Front Oncol 10:588134, 2020. PMID: 33178614.
6. Neelapu SS. CAR-T efficacy: is conditioning the key?. Blood 133(17):1799-1800, 2019. PMID: 31023743.
7. Neelapu SS, Sharma P. Targeting the tumor niche to treat cancer. Proc Natl Acad Sci U S A 112(42):12907-8, 2015. PMID: 26450879.
8. Neelapu SS. Mutations and microenvironment collude in FL. Blood 125(4):587-9, 2015. PMID: 25614636.
9. Neelapu SS, Kwak LW. Rush hour traffic: directing T cells to tumor. J Natl Cancer Inst 106(11), 2014. PMID: 25255804.
10. Neelapu SS, Kwak LW. Cancer vaccines: up, down, ... up again?. Blood 113(1):1-2, 2009. PMID: 19122114.

Abstracts

1. Manasanch EE, Korde N, Lee HC, Patel K, Becnel M, Berrios D, Thomas SK, Iyer SP, Mailankody S, Amini B, Lin P, Berkova Z, Weber DM, Feng L, Neelapu SS, Jagannath S, Hildebrandt MAT, Orlowski RZ, Landgren O. ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM). ASCO - Journal of Clinical Oncology 41(Suppl 16), 2023.
2. Locke FL, Lekakis LJ, Eradat H, Munoz J, Tees MT, de Vos S, Nath R, Stevens DA, Malik S, Popplewell L, Hamadani M, Oluwole OO, Perales M-A, Miklos DB, Fisher P, Goyal L, Kaufman G, Kai K, Balakumaran A, Neelapu SS. Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL). ASCO - Journal of Clinical Oncology 41(Suppl 16), 2023.
3. Neelapu SS, Hamadani M, Miklos DB, Holmes H, Hinkle J, Kennedy-Wilde J, Maller O, Weinstein M, Galimi F, Lai R, Stevens DA. A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022.
4. Cherng H-JJ, Alig S, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister FB, Rodriguez MA, Lee HJ, McDonnell T, Flowers C, Vega F, Green MR, Alizadeh AA, Richard Davis E, Westin J. Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022.
5. Steiner RE, Strati P, Flowers C, Neelapu SS, Green MR, Nastoupil LJ, Hagemeister FB, Feng L, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Westin J. Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022.
6. Jain P, Wang Y, Locke FL, Munoz J, Beitinjaneh A, Frank MJ, Dahiya S, Jacobs MT, Hill BT, Lekakis LJ, Miklos DB, Ghobadi A, Neelapu SS, Lin Y, Wang M, Jain MD, Maurer MJ. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium. ASCO - Journal of Clinical Oncology 40(Suppl 2), 2022.
7. Mamlouk O, Strati P, Feng L, Sun R, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022.
8. Neelapu SS, Stevens DA, Hamadani M, Frank MJ, Holmes H, Jacobovits A, Hinkle J, Kennedy-Wilde J, Maller O, Weinstein B, Galimi F, Lai RK, Miklos DB. A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies. American Society of Hematology - Blood 140(Suppl 1):4617-4619, 2022.
9. Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Owen J, Kanters S, Bobillo S, Ribeiro MT, Jacobson CA, Neelapu SS, Ghesquieres H, Nahas M, Beygi S, Patel AR, Gribben JG. A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). American Society of Hematology - Blood 140(Suppl 1):4676-4677, 2022.
10. Strati P, Li X, Deng D, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, Ahmed S, Chihara D, Fayad L, Iyer SP, Horowitz SB, Nehlsen R, Nastoupil LJ, Ranjit Nair R, Hassan A, Daoud T, Hawkins M, Samaniego F, Rodriguez MA, Shpall EJ, Kebriaei P, Flowers CR, Hong D, Westin J, Neelapu SS, Green MR. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):7493-7495, 2022.
11. Zhang T, Wang Z, Cha S-C, Anderson A, Liu J, Dong Z, Szymura S, Kuang B, Oh E, Neelapu SS, Kwak LW. Development of a Novel Platform for in-Vitro Immune-Monitoring of Antigen-Specific T Cells and Discovery of Novel Antigen-Specific TCRs Using Immortalized B Cells Transfected with mRNA of Antigen Fused to Mitd (IBMAM). American Society of Hematology Blood 140(Suppl 1):4699-4700, 2022.
12. Kevin Tang, Raamis Khwaja, Lei Feng, Paolo Strati, Raphael E. Steiner, Ranjit Nair, Christopher R. Flowers, Neeraj Saini, Jeremy L. Ramdial, Samer A. Srour, Richard E. Champlin, Gabriela Rondon, Janet Torres, Partow Kebriaei, Loretta J. Nastoupil, Haleigh Mistry, Elizabeth J. Shpall, Yago Nieto, Jason Westin, Sattva S. Neelapu, Sairah Ahmed. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy. American Society of Hematology Blood 140(Suppl 1):4684-4685, 2022.
13. Locke FL, Neelapu SS, Ray MD, Limbrick-Oldfield EH, Wade SW, Kanters S, Patel AR, Oluwole OO. Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies. American Society of Hematology Blood 140(Suppl 1):7516-7518, 2022.
14. Khouri IF, Hwang H, Neelapu SS, Wang X, Hosing C, Ahmed S, Kebriaei P, Daher M, Olson AL, Anderlini P, Im JS, Westin J, Shpall EJ, Champlin RE, Nastoupil LJ. Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30. American Society of Hematology Blood 140(Suppl 1):7502-7503, 2022.
15. Neelapu SS, Chavez J, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Joseph JD, Yan J, Song Q, Peng W, Lui C, Wulff J, Shen RR, Poddar S, Miao H, Beygi S, Jacobson CA. 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). American Society of Hematology Blood 140(Suppl 1):10380-10383, 2022.
16. Jain H, Karulkar A, Sharma N, Sengar M, Jaiswal A, Shah S, Khan A, Firfiray A, Asija S, Suvasia P, Suvasia P, Pendhari J, Kalra D, Ravikumar S, Narula G, Banavali S, Poojary M, Hiregoudar S, Nayak L, Bagal B, Tembhare PR, Epari S, Khattry N, Patkar N, Gujral S, Shet T, Subramanian PG, Thorat J, Punatar S, Gokarn A, Ghosh K, Agarwal A, Desai P, Ojha S, Yadav S, Bhosale SP, Rajadhyaksha S, Navkudkar A, Laskar S, Mirgh SP, Nisar A, Pandit D, Patil R, Purwar R, Neelapu SS, Shah NN. Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy. American Society of Hematology Blood 140(Suppl 1), 2022.
17. Oluwole OO, Kenderian SS, Shiraz P, Karmali R, Reshef R, McCarthy PL, Ghosh N, Lazaryan A, Filosto S, Poddar S, Mao D, Peng A, Kilcoyne A, Nahas M, Neelapu SS. ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):10318-10320, 2022.
18. Olalekan O. Oluwole, Saad S. Kenderian, Parveen Shiraz, Reem Karmali, Reshef R, McCarthy PL, Ghosh N, Lazaryan A, Filosto S, Poddar S, Mao S, Peng P, Kilcoyne A, Nahas M, Neelapu SS. ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):10318–10320, 2022.
19. Pinnix CC, Dabaja BS, Gunther JR, Fang P, Wu S, Ahmed S, Steiner RE, Nair R, Strati P, Westin J, Fayad L, Iyer SP, Rodriguez MA, Lee HJ, Samaniego F, Chihara D, Jain P, Feng L, Flowers CR, Neelapu SS, Nastoupil LJ. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):3741–3743, 2022.
20. Li X, Deng Q, Henderson J, Watson G, Deaton L, Cain T, Fayad L, Iyer SP, Hagemeister FB, Nastoupil LJ, Fowler NH, Westin J, Steiner R, Nair R, Ahmed S, Alatrash G, Neelapu SS, Strati P, Green MR. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy. American Society of Hematology Blood 140(Suppl 1):4502–4503, 2022.
21. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MA, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Malpica Castillo LE, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros LJ, Marques-Piubelli ML, Vega F, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer SP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. American Society of Hematology Blood 140(Suppl 1):3800-3802, 2022.
22. Lunning MA, Wang H-L , Hu Z-H, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Miao H, Shahani S, Patel AR, Spooner C, Fu C, Xu H, Pasquini MC. Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy. American Society of Hematology Blood 140(Suppl 1):1852-1855, 2022.
23. Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Fayad L, Jain P, Wang ML, Miranda RN, Vega F, Medeiros J, Oki Y, Flowers CR, Neelapu SS, Iyer SP. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. American Society of Hematology Blood 140(Suppl 1):2313-2315, 2022.
24. Nair R, Prakash R, Dang A, Gunther JR, Huen A, Xu J, Malpica Castillo LE, Cabala CT, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Ramdial JL, Nieto Y, Nastoupil LJ, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing C, Wang ML, Dabaja BS, Vega F, Feng L, Iyer SP. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):12005-12007, 2022.
25. Jallouk A, Feng L, Noorani M, Das K , Steiner RE, Nastoupil LJ, Hawkins M, Nair R, Westin J, Fayad L, Chihara D, Malpica Castillo LE, Iyer SP, Ahmed S, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy. American Society of Hematology Blood 140(Suppl 1):10424-10426, 2022.
26. Sheng A, Gordon MJ, Ahmed S, Steiner RE, Strati P, Westin J, Hosing C, Kebriaei P, Shpall EJ, Neelapu SS, Nastoupil LJ. Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies. American Society of Hematology Blood 140(Suppl 1):2051-2052, 2022.

Letters to the Editor

1. Gribben J, Palomba ML, Patel AR, Nahas M, Neelapu SS. Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma. Blood Adv 7: 2494-2495, 2023.